Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed‐Methods Study
European Journal of Neurology · 2025
DOI: 10.1111/ene.70183 ↗At a glance
Journal article in European Journal of Neurology, 2025. Written by Chloe Pierret and 2 co-authors. Institution: Rennes University, EHESP, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, Rennes, France. Major MEDLINE topics: Multiple Sclerosis, Breast Neoplasms, Mammography, Early Detection of Cancer. 34 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques, EDMUS Foundation, Institut des Neurosciences Cliniques de Rennes.
Abstract (original language)
Background
There is little information on breast cancer screening (BCS) practices in women with multiple sclerosis (WwMS).
Objective
To assess and compare BCS rates in WwMS and in the general population and identify barriers and facilitators.
Methods
In a 2012–2020 cohort study, we identified 47,166 WwMS without a history of cancer and matched them (up to 1:4) to 184,124 controls from the French national medico‐administrative database. Mammography rates were compared according to age, city‐level socio‐economic status, period, and DMT use. We used logistic and negative binomial models to identify factors associated with BCS adherence in WwMS. We also carried out semistructured interviews with 20 WwMS and analyzed them using the empirically inductive method.
Results
Compared with controls, fewer WwMS underwent BCS at least once (69.9% vs. 76.7%, p < 0.001) and had a lower biennial mammography rate (0.55 vs. 0.63; p < 0.001). Rate differences increased with age. Once stratified on DMT, age‐standardized rates only differed in the non‐treated group (0.51 vs. 0.64; p < 0.001). Factors associated with lower mammography rates in WwMS were city‐level socio‐economic status (mostdeprived vs. least deprived; IRR 0.88 95% CI [0.86–0.91]), long MS duration (16–25 years: 0.91 [0.89–0.94]; ref: ≤ 5) and hospitalization (MS‐related: 0.85 [0.82–0.88]; non‐MS‐related: 0.92 [0.89–0.94]). However, DMT use was associated with higher mammography rates (high efficacy: 1.17 [1.14–1.21]; moderate efficacy: 1.18 [1.16–1.20]). Barriers were physical disability and feeling of excessive medicalization. Facilitators were disability‐accessible care and perception of BCS as a routine procedure.
Conclusion
BCS among WwMS is suboptimal, especially among those not treated by DMT, and needs to be improved.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Rennes University, EHESP, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, Rennes, France.
ORCID profiles: Chloe Pierret, Emmanuelle Leray
Funding
- Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques
- EDMUS Foundation
- Institut des Neurosciences Cliniques de Rennes
- Matmut Paul Bennetot Foundation - INSPIRE Chair
Cite
APA
Pierret, C., Philippe, L., & Leray, E. (2025). Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed‐Methods Study. European Journal of Neurology. https://doi.org/10.1111/ene.70183
Vancouver
Pierret C, Philippe L, Leray E. Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed‐Methods Study. European Journal of Neurology. 2025. doi:10.1111/ene.70183
BibTeX
@article{Pierret2025,
author = {Pierret, Chloe and Philippe, Lou and Leray, Emmanuelle},
title = {Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed‐Methods Study},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70183}
}
EUVIMED